Stock
Guru

What happenedOrganic ramp of two in-house launched products: iDose TR (sustained-release travoprost implant, ~$76M in Q3 2026) drove the Glaucoma segment to $118.6M (+47%), while Epioxa (corneal cross-linking) powered Corneal Health to $59.0M (+154%); total Q3 net sales $211.0M, +58% YoY vs a $133.5M year-ago base. Gross margin expanded to ~85% GAAP (from 78%) on favourable mix toward these high-margin drug/device products.

BullGrowth is broad-based across two self-launched products with margin expansion and a raised FY2026 guide ($775-785M) plus a preliminary 2027 target of $1B; Q3 Phase 4 data showed iDose TR + cataract beat surgery alone on all endpoints with a clean durability/safety profile, reinforcing clinical adoption. iDose carries a permanent J-code (J7355) with pass-through reimbursement and improving MAC/Medicare Advantage coverage.

BearThe YoY comp is flattered by a depressed 2025 base (MAC LCD restrictions suppressed legacy MIGS/stent sales), iDose transitional pass-through status is finite (J7355 effective Jul 1 2024, so pass-through likely lapses around end-2027 - a reimbursement cliff I could not firmly date), and after a ~33% single-day pop to ~$240 with analysts hiking targets, high expectations are now priced in.

NarrativeStrongly bullish post-print - stock surged ~33% to ~$240.52 on 29 Oct 2026 and multiple sell-side analysts raised targets (Needham $251, BTIG $234, Stifel $225, all Buy), though it was down ~32% YTD beforehand. Note some momentum/retail-trading coverage signalling hype - mild caution - with the 2027 $1B guide and the eventual pass-through status review as the key forward catalysts.

What happenedRecord Q3 2026 net sales of $1,005.7M (+24.6% YoY vs $807.1M in Q3 2025, reported 2026-10-29) driven by unit/wafer-start volume growth that accelerated to ~20% in Q3 from ~6% in Q1, backlog conversion, and rising materials intensity at leading-edge logic and memory (AI-driven complexity, SLC/HBM-adjacent storage) that expands content per wafer. Growth came despite prior divestitures (PIM divested Q1 2024, electronic chemicals earlier) that reduce the revenue base, making it more notable.

BullUnit-driven growth accelerated each quarter (6%->20%), book-to-bill significantly above 1, backlog up >35% sequentially and more than doubled YoY, with plan-of-record design wins (CMP material at a leading memory provider, EUV filtration for 2nm) that lock in recurring content as nodes advance; Q4 guide of $1.025-1.055B (~26% YoY at midpoint) confirms sustained momentum into 2027.

Bear2025 was a weak semi/memory comp so part of the +24.6% is an easy base, and APS (+31.2%) includes capex-sensitive equipment sales that are lumpier than the consumables story; the stock is already +~90% YTD so the inflection looks largely priced in, and a leading-edge capex or memory digestion pause would de-rate it fast.

NarrativeStrongly positive quarter - beat on revenue ($1.006B vs ~$926M consensus) and adj EPS ($1.23 vs ~$1.02), above-consensus Q4 guide, 25-year-high margins and record backlog; analyst tone constructive. Caution: shares already +~90% YTD (~$159, ~15% below 52-week high), so expectations are elevated; no evident frothy retail hype, narrative is institutional/fundamental. Catalysts: Q4 print, 2027 capex commentary, continued leading-edge/memory ramp.

What happenedQ3 2026 revenue of $1.423B (+26.5% YoY) was driven by the aerospace & defense ramp, which is now ~69% of sales: commercial jet-engine sales nearly doubled YoY on next-gen engine production (containing >2x the material content of legacy engines), plus record defense/missile demand (Tomahawk, THAAD, PAC-3). Management split the growth as roughly two-thirds price/mix and one-third volume, with the price/mix piece attributed to long-term agreements and a deliberate exit from commodity stainless, not raw-material surcharge pass-through.

BullBacklog hit $4.3B (+20% YoY, near record) with 20+ month titanium lead times and 2+ year forging lead times giving multi-year visibility; management says jet-engine demand so exceeds supply that 'if we doubled production today they would take it all,' airframe inventories are normalized, and margin/mix gains are 'structurally transformed' via LTAs rather than temporary pricing. Full-year EBITDA guide raised again to ~$1.195B.

BearOnly about one-third of the growth was true volume; two-thirds was price/mix, so a chunk depends on pricing and richer mix that could normalize, and the stock has already re-rated hard (Wells Fargo PT $275 from $175, Deutsche $262, Strong Buy consensus) leaving the super-cycle largely priced in ahead of the Nov 12 Investor Day. Boeing/Airbus destocking remains a latent risk even if not yet visible.

NarrativeStrongly bullish institutional reaction - multiple post-print price-target raises (Wells Fargo to $275, Deutsche to $262, Susquehanna to $265), Strong Buy consensus, EBITDA at highest since 2007; catalyst is the Nov 12 2026 Investor Day where new long-term targets are expected. Narrative is analyst/institution-led, not retail meme hype.

What happenedQ3 2026 revenue rose 31.7% ($1.42B to $1.87B) and brokerage revenue 38%, but brokerage volume grew only ~2% (truckload +3%) - the jump is almost entirely rate/pricing: spot mix surged to 51% from 29% a year earlier and gross profit per load rose 31% sequentially, reflecting the 2026 truckload freight-cycle rate recovery. It is NOT Coyote: that deal closed 16 Sep 2024 and was fully in the 2025 comparison base, so it had lapped by Q4 2025.

BullA genuine, capacity-driven freight-market inflection is underway - industry spot rates up ~38% YoY, contract-spot gap compressing, 72% of brokers expecting further tightening - and RXO is taking share (truckload volume outperformed a flat market, improving every month), which turned the business profitable (GAAP net income $3M vs -$14M; adj EBITDA $51M vs $32M, beating its own $35-45M guide).

BearGrowth is cyclical pricing, not organic volume (only +2%), and spot rates are volatile - they already fell in mid-August 2026 - so the comps mean-revert when the cycle rolls; gross margin actually compressed to 14.6% from 16.5%. The story is moot as a standalone equity: RXO agreed on 4-5 Oct 2026 to be bought by C.H. Robinson for $30.25/share (~$5.8B, closes H1 2027), so the stock is now merger arb capped at the deal price, not a growth vehicle.

NarrativeNo Q3 earnings call was held because of the pending C.H. Robinson deal, so analyst commentary is thin; the narrative has shifted entirely to merger arbitrage around the $30.25/share offer (29% premium) rather than organic fundamentals. Main catalysts are the shareholder vote and regulatory approval into H1 2027, not operating results.

What happenedThe 21.2% revenue jump (Q3 2026, reported 21 Oct 2026) was almost entirely unit-revenue/pricing, not volume: RASM +21.6% and passenger yield +23.3% to all-time records, while capacity (ASM) and traffic (RPM) were both down 0.4% and passengers carried fell 3.2%. The driver is Southwest's 2025-26 commercial overhaul - new checked-bag fees (~$1B EBIT in 2026), assigned/extra-legroom premium seating (~$1B EBIT targeted 2027), basic economy and Rapid Rewards changes - plus fare increases (average fare +26.9% YoY).

BullThe revenue/margin step-up is real cash, not accounting noise: adjusted operating margin +4.8pts and operating income ~+983%; management says ~two-thirds of unit-revenue outperformance is underlying strength, RASM beat its own 17.5-19.5% guide, and Q4 is guided to +19-21% RASM with the 2027 seating ramp still ahead - so the higher revenue/profit level is durable.

BearThis is monetization of a flat-to-shrinking customer base, not organic demand - passengers carried fell 3.2% and traffic was negative, so the entire gain is price/self-help. The 21% YoY growth rate is a one-time re-rating from initiatives rolled out through 2025 (bags effective ~May 2025, assigned seating early 2026); once fully lapped in 2027 the growth decelerates sharply. Fuel +63% to $3.92/gal and a cut full-year profit forecast underline the fragility.

NarrativePositive but measured: stock rose on the Q3 beat (adj EPS $0.66 vs $0.57, +500% YoY) and record RASM, yet several analysts flagged the cut full-year EPS guide ($2.60-$2.85) on fuel and the fact that gains are self-help lapping rather than demand. Not a heavy retail-hype name; key 2027 catalyst is the seating-monetisation ramp and whether volumes stabilise.